News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
85 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38485)
2025 (24062)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3635)
June (2415)
July (2091)
August (2656)
September (1716)
Day
1 (86)
3 (15)
4 (50)
5 (135)
6 (195)
7 (196)
8 (198)
9 (1)
11 (66)
12 (179)
13 (160)
14 (111)
15 (154)
18 (92)
19 (96)
20 (122)
21 (99)
22 (68)
24 (15)
25 (85)
26 (160)
27 (80)
28 (176)
29 (117)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
Day
1
3
4
5
6
7
8
9
11
12
13
14
15
18
19
20
21
22
24
25
26
27
28
29
Obesity
Weight-Loss Wasteland: 5 Obesity Assets That Failed
The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and losers. Here are five molecules that never made it to the market.
August 25, 2025
·
9 min read
·
Tristan Manalac
Regulatory
FDA To Publish Drug-Related Adverse Event Reports Daily
The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a quarterly basis.
August 25, 2025
·
2 min read
·
Tristan Manalac
Government
HHS Will No Longer Recognize Employee Unions
Thousands of employees across the Department of Health and Human Services are set to lose their collective bargaining rights in a move that American Federation of Government Employees national president Everett Kelley called “illegal and immoral.”
August 25, 2025
·
2 min read
·
Tristan Manalac
Vaccines
FDA Pulls Valneva’s Chikungunya Shot From Market Citing ‘Serious Safety Concerns’
Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the regulator has reversed course.
August 25, 2025
·
2 min read
·
Tristan Manalac
Startups
Arnatar Debuts With $52M To Advance RNA Therapies That Go Beyond Silencing
Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare disease called Alagille syndrome.
August 25, 2025
·
2 min read
·
Tristan Manalac
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.
August 25, 2025
·
3 min read
·
Annalee Armstrong
IPO
Biotech Finally Has an IPO After Months-Long Freeze
LB Pharma will test the IPO market to seek funding for a Phase III-ready schizophrenia asset.
August 25, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
August 25, 2025
·
10 min read
Press Releases
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints
August 25, 2025
·
5 min read
Press Releases
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
August 25, 2025
·
7 min read
1 of 9
Next